Targeting IL-17 for pancreatic cancer prevention

Oncotarget. 2014 Oct 30;5(20):9530-1. doi: 10.18632/oncotarget.2618.

Authors

Florencia McAllister¹, Steven D Leach²

Affiliations

¹ Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX.
² The David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY.

No abstract available

Publication types

Editorial

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / immunology
Aspirin / administration & dosage
Carcinoma, Pancreatic Ductal / prevention & control*
Humans
Interleukin-17 / antagonists & inhibitors
Interleukin-17 / immunology*
Molecular Targeted Therapy
Pancreatic Neoplasms / immunology
Pancreatic Neoplasms / prevention & control*

Substances

Anti-Inflammatory Agents, Non-Steroidal
Antibodies, Monoclonal
Interleukin-17
Aspirin